Drug Profile
EP 202
Alternative Names: EP-202Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator EpiThany; University of Washington
- Class Antigens; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer
Most Recent Events
- 22 Sep 2023 Preclinical development in ovarian cancer is underway in USA (EpiThany pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (Parenteral)
- 05 Oct 2016 Preclinical trials in Ovarian cancer in USA (Parenteral) (EpiThany pipeline, October 2016)